Result of AGM

RNS Number : 3317Q

Medica Group PLC

27 June 2022

 

27 June 2022

Medica Group Plc

Result of Annual General Meeting

Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK and Ireland market leader in the provision of teleradiology services, announces that, at its Annual General Meeting held at 11.00am today, all resolutions put to the meeting were duly passed.

Details of the voting are as follows:

Resolution		For/ Discretion (Number of votes)	% For/ Discretion	Against (Number of votes)	% Against	Total votes	Withheld (Number of votes)
Ordinary Business
1.	To receive and adopt the annual report, accounts and the auditor's report	100,735,575	100.00	0	0.00	100,735,575	1,173,666
2.	To approve the Directors' Remuneration Report (excluding Remuneration Policy)	100,703,036	99.72	279,222	0.28	100,982,258	926,983
3.	To approve the amendments to the rules of the Performance Share Plan	100,165,535	99.19	814,918	0.81	100,980,453	928,788
4.	To declare a final dividend	100,985,486	100.00	0	0.00	100,985,486	923,755
5.	To re-appoint Grant Thornton UK LLP as auditors	100,731,909	99.995	4,728	0.005	100,736,637	1,172,604
6.	To authorise the directors to determine the remuneration of the auditors	100,981,201	100.00	0	0.00	100,981,201	928,040
7.	To re-elect Roy Davis as a Director	101,032,592	99.21	807,948	0.79	101,840,540	68,701
8.	To re-elect Joanne Easton as a Director	101,516,659	99.67	340,582	0.33	101,857,241	52,000
9.	To re-elect Dr Junaid Bajwa as a Director	99,013,524	97.97	2,048,111	2.03	101,061,635	847,606
10.	To re-elect Stuart Quin as a Director	101,834,429	99.98	20,355	0.02	101,854,784	54,457
11.	To re-elect Richard Jones as a Director	101,602,107	99.998	2,028	0.002	101,604,135	305,106
12.	To elect Barbara Moorhouse as a Director	101,850,479	100.00	0	0.00	101,850,479	58,762
Special Business
13.	General authority to allot shares pursuant to Section 551 Companies Act 2006	100,912,668	99.93	68,956	0.07	100,981,624	927,617
14.	General authority to allot equity securities pursuant to Section 570 Companies Act 2006	94,241,011	93.32	6,742,613	6.68	100,983,624	925,617
15.	General authority to allot equity securities pursuant to Section 570 Companies Act 2006 for the purpose of financing an acquisition or other capital investment	94,240,212	93.32	6,742,717	6.68	100,982,929	926,312
16.	Authority to make market purchases of up to 12,242,883 shares	100,680,388	99.75	253,649	0.25	100,934,037	975,204
17.	To authorise the general meeting to be held on 14 clear days' notice	100,117,101	99.14	867,690	0.86	100,984,791	924,450

For further information, please contact:

Medica Group Plc: Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer	[phone]
FTI Consulting Victoria Foster Mitchell Sam Purewal	[phone]
Liberum (Joint Broker) Phil Walker Richard Lindley	[phone]
Numis (Joint Broker) Freddie Barnfield Duncan Monteith Euan Brown	[phone]

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition,  Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

The Company currently offers two primary services to hospital radiology departments:

·   NightHawk - urgent reporting service

·   Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit:  www.medicagroupplc.com  

 

END

 

 

RAGEAAKXASKAEFA